Hexagon Capital Partners LLC Argenx Se Transaction History

Hexagon Capital Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	SELL	$369.35 - $548.43 $369 - $548	-1 Reduced 50.0%	1 $0
Q2 2023 Jul 24, 2023	SELL	$360.14 - $422.58 $360 - $422	-1 Reduced 33.33%	2 $0
Q1 2023 Apr 24, 2023	SELL	$334.23 - $403.65 $668 - $807	-2 Reduced 40.0%	3 $1,000
Q3 2022 Oct 17, 2022	BUY	$343.2 - $395.75 $1,029 - $1,187	3 Added 150.0%	5 $2,000
Q2 2022 Jul 21, 2022	BUY	$269.58 - $378.88 $539 - $757	2 New	2 $1,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Hexagon Capital Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Hexagon Capital Partners LLC with notifications on news.